Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia
about
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaGene-environment interplay between cannabis and psychosisThe role of cannabinoid 1 receptor expressing interneurons in behavior.Postmortem brain: an underutilized substrate for studying severe mental illnessSensory gating impairments in heavy cannabis users are associated with altered neural oscillations.Decreased parvalbumin immunoreactivity in the cortex and striatum of mice lacking the CB1 receptor.Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapiesDevelopment of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex.Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder.Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophreniaIncreased cortical inhibition deficits in first-episode schizophrenia with comorbid cannabis abuseVulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis.Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia.Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortexBiodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental modelsPostnatal developmental trajectories of neural circuits in the primate prefrontal cortex: identifying sensitive periods for vulnerability to schizophrenia.Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia.Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studiesMedical use of cannabis. Cannabidiol: a new light for schizophrenia?Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia.Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortexLower glutamic acid decarboxylase 65-kDa isoform messenger RNA and protein levels in the prefrontal cortex in schizoaffective disorder but not schizophreniaSelective pyramidal cell reduction of GABA(A) receptor α1 subunit messenger RNA expression in schizophrenia.Cortical glutamic acid decarboxylase 67 deficiency results in lower cannabinoid 1 receptor messenger RNA expression: implications for schizophrenia.Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trialCortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features.Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence.New insights on endocannabinoid transmission in psychomotor disorders.Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophreniaEndocannabinoids via CB₁ receptors act as neurogenic niche cues during cortical development.The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies.Endocannabinoid system: potential novel targets for treatment of schizophrenia.Endocannabinoid metabolism in the prefrontal cortex in schizophrenia.Rethinking schizophrenia in the context of normal neurodevelopmentReduced Brain Cannabinoid Receptor Availability in Schizophrenia.
P2860
Q24607361-C891BEF7-75EF-4478-A7E4-552450AD0D09Q24643510-7AA732B0-2F64-40B6-A921-26B44C0CD7D6Q30417825-D38007FB-CBF1-4F1D-BF2F-53EF1351A36EQ30422050-8C682464-F25A-4B6B-9F46-52ED6A082866Q30459343-A17406FA-F2AB-4493-99E7-25E33B235A68Q30465324-8EF9525D-E594-4F82-89B3-99421874EBA2Q30473707-A39CD4B3-138E-4E08-944F-C48F12B2B23AQ30484459-862A05C6-EA8B-49E7-9FCF-DE4C0E963372Q30494037-AEEB1F83-B19D-451C-ACE8-1C59CE2856E2Q30497212-E27E5D84-300C-4D0D-AE15-E7548C717D23Q30499642-5586A19E-3FAE-42C0-9CE2-864F8BC74837Q33590705-B97BDB26-4E97-458E-9DA2-310A4FB9BA72Q33664684-29FA22E1-22D1-4BCD-9524-008EA6048293Q33921361-55349A28-C223-4C73-915C-D7CC51DD6116Q34026425-DA365461-4F44-42FD-9A40-E34F524CBF24Q34044002-C2EA30B5-E1DB-460B-A8B2-79C161F207EAQ34098209-2A4B23DD-56C0-4751-809F-A1DFB221AA9AQ34179419-35EE29E8-925E-428E-94DB-162808DCD935Q34254840-FBBAEE17-6617-459D-99F7-B05F41CBC833Q34282907-E36A83EB-A3E3-4B91-9C01-3401B1B272A5Q34308885-52F669A2-224E-4CBB-8481-B775D3AA99A5Q34384480-7E5CD2A4-89EA-43B1-A0F2-AD31256A71FFQ34536072-FB24C394-DF51-46D8-8950-DDECB4F733D4Q34587796-51FA125A-5B5C-45E0-B344-055F2598681EQ35171300-76F30921-FCDB-4E3C-9E28-6C25384AFD47Q35612878-05B27239-9539-4145-BE75-D43BED8FAB76Q35713057-45C53266-6C99-40BD-BE18-0173A1AD6233Q35740484-BBAD6FB1-9DE6-423B-82A2-9C39E163BF5AQ35784024-C8BCFC4E-D257-478C-AC0C-F0BD5390593CQ36074595-EFA3800D-E51D-418D-81FF-5E2341FF471BQ36189837-785CDC86-A6C1-45C7-ADB8-582EB509F349Q36295963-67FBE22F-E791-43F5-88F6-3F9C8B5B09AAQ36348362-CCB3806D-50D3-4DA4-8539-B99E82EE6D1CQ36386484-5CD49333-1707-458C-8C20-F9C2EAAC9360Q36417706-C72B43B5-CD02-4E9A-9597-127F3592A7FAQ36612284-F16929B4-DDDD-41B6-8E37-0B45C7A462B0Q36675661-2BB09FD1-BE36-4A6B-8710-022905804C6BQ36831875-7AA25D03-E9C8-49DE-9E1E-B9963917DA03Q36844622-FE78531D-DACA-4AF8-A13B-80A31A31E95FQ36945634-A1A04C9C-504B-48A7-84FF-28DEA2CFE3D0
P2860
Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Reduced cortical cannabinoid 1 ...... in expression in schizophrenia
@ast
Reduced cortical cannabinoid 1 ...... in expression in schizophrenia
@en
type
label
Reduced cortical cannabinoid 1 ...... in expression in schizophrenia
@ast
Reduced cortical cannabinoid 1 ...... in expression in schizophrenia
@en
prefLabel
Reduced cortical cannabinoid 1 ...... in expression in schizophrenia
@ast
Reduced cortical cannabinoid 1 ...... in expression in schizophrenia
@en
P2860
P921
P1433
P1476
Reduced cortical cannabinoid 1 ...... in expression in schizophrenia
@en
P2093
Stephen M Eggan
Takanori Hashimoto
P2860
P304
P356
10.1001/ARCHPSYC.65.7.772
P407
P577
2008-07-01T00:00:00Z